Zevra Therapeutics has filed a patent for a method of using a neurokinin receptor (NK) antagonist to block or reduce vasomotor symptoms (VMS) in cancer patients undergoing hormone deprivation therapy or medical/surgical procedures that may cause VMS. The method aims to alleviate VMS in patients with cancer or an increased risk for cancer. GlobalData’s report on Zevra Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Zevra Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Zevra Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Zevra Therapeutics's grant share as of September 2023 was 44%. Grant share is based on the ratio of number of grants to total number of patents.

Method of using a nk antagonist to treat vasomotor symptoms in cancer patients

Source: United States Patent and Trademark Office (USPTO). Credit: Zevra Therapeutics Inc

A recently filed patent (Publication Number: US20230277518A1) describes a method for blocking or reducing the development of vasomotor symptoms (VMS) in cancer patients undergoing hormone deprivation therapy or other medical procedures that may cause VMS. The method involves administering a neurokinin receptor (NK) antagonist to the patient prior to and optionally concurrently with the therapy or procedure.

The patent claims specify that the NK antagonist can be a neurokinin-3 receptor (NK3) antagonist, such as osanetant, fezolinetant, pavinetant, talnetant, SB-222,200, SB-218,795, NT-814, or their stereoisomers, mixtures, prodrugs, salts, hydrates, solvates, acid salt hydrates, N-oxides, or isomorphic crystalline forms. The effective amount of osanetant is less than 400 mg per day, with a range of 10 to 350 mg per day or 10 to 150 mg per day.

The method can be used for various types of cancer, including breast, ovarian, uterine, and prostate cancer, particularly hormone receptor-positive cancer. It can also be used for patients who have tested positive for BRCA1, BRCA2, or PALB2 mutations. The time period for administering the NK antagonist prior to the therapy or procedure can range from 12 weeks to one week.

In addition to the NK antagonist, the method can involve administering other therapeutic agents, such as selective estrogen receptor modulators (SERMs) like tamoxifen, gonadotropin-releasing hormone (GnRH) agonists or antagonists like leuprolide, nonsteroidal antiandrogens, kappa opioid agonists, or selective estrogen receptor degraders (SERDs).

The patent also claims that the method can alleviate social isolation stress in cancer patients.

Overall, this patent describes a method for using a neurokinin receptor antagonist, particularly an NK3 antagonist like osanetant, to block or reduce vasomotor symptoms in cancer patients undergoing hormone deprivation therapy or other medical procedures. The method can be tailored to different types of cancer, patient characteristics, and treatment durations, and may involve the use of additional therapeutic agents.

To know more about GlobalData’s detailed insights on Zevra Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies